PHASE 2 STUDY OF ALDOXORUBICIN VERSUS TOPETECAN FOR RELAPSED/REFRACTORY SMALL CELL LUNG CANCER

被引：0
|
作者：
Wieland, S. [1 ]
Mita, A. [2 ]
Piantadosi, S. [2 ]
Natale, R. [2 ]
Levitt, D. [3 ]
机构：
[1] CytRx Corp, Clin Operat, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] CytRx Corp, Clin Dev, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu355.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1478TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 Study of Aldoxorubicin versus Topotecan for Relapsed/Refractory Small Cell Lung Cancer
    Chawla, Shanta
    Wieland, Scott
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S742 - S742
  • [2] A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer
    Han, Ji-Youn
    Kim, Hyae Young
    Lim, Kun Young
    Han, Jong Hee
    Lee, You Jin
    Kwak, Mi Hyang
    Kim, Hak Jin
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    LUNG CANCER, 2013, 79 (02) : 137 - 142
  • [3] Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer
    Yamamoto, N
    Tsurutani, J
    Yoshimura, N
    Asai, G
    Moriyama, A
    Nakagawa, K
    Kudoh, S
    Takada, M
    Minato, Y
    Fukuoka, M
    ANTICANCER RESEARCH, 2006, 26 (1B) : 777 - 781
  • [4] Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer
    Yoshioka, Hiroshige
    Kogure, Yoshihito
    Ando, Masahiko
    Kitagawa, Chiyoe
    Iwasaku, Masahiro
    Niwa, Takashi
    Saka, Hideo
    IN VIVO, 2018, 32 (06): : 1581 - 1586
  • [5] Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
    Pietanza, M. Catherine
    Travis, William D.
    Chan, Timothy A.
    Ginsberg, Michelle S.
    Kris, Andrei Holodny Mark G.
    Krug, Lee M.
    PANCREAS, 2010, 39 (02) : 279 - 279
  • [6] Phase II study of temozolomide for relapsed sensitive or refractory small cell lung cancer
    Pietanza, Maria Catherine
    Pereira, Leanne
    Dunne, Meghan
    Travis, William D.
    Chan, Timothy A.
    Ginsberg, Michelle S.
    Holodny, Andrei
    Kris, Mark G.
    Krug, Lee M.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S819 - S820
  • [7] Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer
    Hirose, T
    Horichi, N
    Ohmori, T
    Ogura, K
    Hosaka, T
    Ando, K
    Ishida, H
    Noguchi, H
    Adachi, M
    LUNG CANCER, 2003, 40 (03) : 333 - 338
  • [8] Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer (SCLC)
    Pietanza, M. C.
    Sima, C. S.
    Polley, M. R.
    Sumner, D. K.
    Travis, V.
    Heguy, A.
    Ginsberg, M. S.
    Holodny, A.
    Kris, M. G.
    Krug, L. M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S507 - S507
  • [9] Phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC)
    Han, J.
    Lim, K. Y.
    Kim, H. Y.
    Han, J. H.
    Oh, S. H.
    Yun, T.
    Kim, H. T.
    Lee, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer
    Byrne, Margaret M.
    Sutamtewagul, Grerk
    Zeitler, William
    Mott, Sarah L.
    Zamba, Gideon K. D.
    Kojadinovic, Arsenije
    Zhang, Jun
    Abu-Hejleh, Taher
    Clamon, Gerald
    Furqan, Muhammad
    FRONTIERS IN ONCOLOGY, 2024, 14
12345